# US 2004/0062776 A1 · Botulinum toxin therapy for fibromyalgia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0062776 A1
- Document ID: US20040062776A1
- Status: Published application
- Kind: A1
- Application number: 10/666,408
- Filed: 2003-09-18
- Published: 2004-04-01
- Earliest claimed: 2001-09-17
- Assignees: Allergan, Inc.
- Inventors: Martin A. Voet
- Web page: https://patentgrep.com/patent/US20040062776A1

## CPC

- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for treating fibromyalgia by administering a therapeutically effective amount of a botulinum toxin to a patient with fibromyalgia.

## Claims

### Claim 1

A method for treating fibromyalgia, the method comprising the step of administering a botulinum toxin to a patient afflicted with fibromyalgia.

### Claim 2 (depends on 1)

The method of claim 1 wherein the botulinum toxin is selected form the group consisting of botulinum toxin types A, B, C, D, E, F and G.

### Claim 3 (depends on 1)

The method of claim 1 wherein the botulinum toxin is a botulinum neurotoxin type A.

### Claim 4 (depends on 1)

The method of claim 1 wherein the botulinum toxin is administered subcutaneously.

### Claim 5 (depends on 1)

The method of claim 1 wherein the botulinum toxin is administered intramuscularly.

### Claim 6

A method for treating a fibromyalgia pain, the method comprising the step of administering locally a therapeutically effective amount of a botulinum neurotoxin to a patient with a fibromyalgia pain, thereby treating the fibromyalgia pain.

### Claim 7 (depends on 6)

The method of claim 6 wherein the botulinum neurotoxin is selected from the group consisting of botulinum neurotoxin types A, B, C, D, E, F and G.

### Claim 8 (depends on 6)

The method of claim 6 wherein the botulinum neurotoxin is a botulinum neurotoxin type A.

### Claim 9 (depends on 6)

The method of claim 6 wherein the botulinum neurotoxin is administered subcutaneously or intramuscularly.

### Claim 10

A method for treating fibromyalgia, the method comprising the step of administering a botulinum toxin to a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.

### Claim 11 (depends on 10)

The method of claim 10, wherein the first location is a peripheral location.

### Claim 12 (depends on 10)

The method of claim 10, wherein the second location is a locus of pain.

### Claim 13 (depends on 10)

The method of claim 10, wherein the administering step is carried out by subcutaneous or intramuscular administering of the botulinum toxin.

### Claim 14 (depends on 10)

The method of claim 10, wherein the first location is the head or neck of the patient.
